Hormonal
Bariatric surgery reverses the sex-specific hormonal imbalances caused by obesity: it increases testosterone in men and decreases testosterone in women, while increasing SHBG and decreasing estradiol in both.
Bariatric surgery normalizes sex hormones in a sex-specific way. Men typically see their testosterone levels rise to normal ranges, while women see their elevated testosterone levels drop. Both groups see an increase in Sex Hormone Binding Globulin (SHBG) and a decrease in Estradiol. This hormonal normalization is key to resolving fertility and sexual health issues associated with obesity.
total testosterone concentration increased in men (8.1 nmol/l... ) but decreased in women (−0.7 nmol/l... ). Sex hormone-binding globulin concentrations increased after bariatric surgery in women... and in men... and serum estradiol concentrations decreased in women... and to a lesser extent in men
Why this rating
Meta-analysis of hormone changes across multiple studies.
Source
Prevalence of ‘obesity-associated gonadal dysfunction’ in severely obese men and women and its resolution after bariatric surgery: a systematic review and meta-analysis
Héctor F. Escobar‐Morreale et al. · Human Reproduction Update · 2017
DOI 10.1093/humupd/dmx012
More from this paper
- Bariatric surgery resolves obesity-associated gonadal dysfunction (PCOS in women, MOSH in men) in the vast majority of severely obese patients, with resolution rates of 96% for PCOS and 87% for MOSH.Strong
- Obesity-associated gonadal dysfunction is highly prevalent in severely obese patients, affecting 36% of women (PCOS) and 64% of men (MOSH).Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →